Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers

Part of the Contemporary Cardiology book series (CONCARD)


Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) play a pivotal role in the management of heart failure (HF) and hypertension. These agents are cardioprotective and increase survival in patients with
  • HF.

  • Feft ventricular (FV) dysfunction.

  • Acute myocardial infarction (MI). The Survival of Myocardial Infarction Fong-Term Evaluation (SMIFE) study (1) showed that zofenopril administered to patients with acute anterior infarction improved survival.

  • Hypertension with FV hypertrophy (FVH).

  • Hypertension with diabetes and proteinuria.

  • A high risk for cardiovascular events, as documented by the Heart Outcomes Prevention Evaluation HOPE study (2).


Isosorbide Dinitrate Scleroderma Renal Crisis Angiotensin Converting Enzyme Gene Angiotensin Converting Enzyme Inhibitor Therapy Bilateral Renal Artery Stenosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ambrosioni E, Borghi C, Magnani B, et al. for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80.PubMedCrossRefGoogle Scholar
  2. 2.
    HOPE Investigators. Yusuf S, Sleight P, Pogue J, et al. The Heart Outcomes Prevention Evaluation Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000;342:145.PubMedCrossRefGoogle Scholar
  3. 3.
    Pfeffer MA, Braunwald E. Ventricular remodelling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990;81:1161.PubMedGoogle Scholar
  4. 4.
    Davis JO, Freeman RH. Mechanisms regulating renin release. Physiol Rev 1976;56:1.PubMedGoogle Scholar
  5. 5.
    Torretti J. Sympathetic control of renin release. Annu Rev Pharmacol Toxicol 1982;22:167.PubMedCrossRefGoogle Scholar
  6. 6.
    Reid IA. The renin-angiotensin system and body function. Arch Intern Med 1985;145:1475.PubMedCrossRefGoogle Scholar
  7. 7.
    Ganong WF. The brain renin-angiotensin system. Annu Rev Physiol 1984;46:17.PubMedCrossRefGoogle Scholar
  8. 8.
    Khan M Gabriel. Heart failure. In: Heart Disease, Diagnosis and Therapy. Totowa, NJ, Humana Press, 2005.Google Scholar
  9. 9.
    Munzel T, Keaney JF. Are ACE inhibitors a “magic bullet” against oxidative stress? Circulation 2001; 104:1571.Google Scholar
  10. 10.
    Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904.PubMedGoogle Scholar
  11. 11.
    Leary WP, Reyes AJ. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drugs Ther 1987;1:29.PubMedCrossRefGoogle Scholar
  12. 12.
    Cicoira M, Zanolla L, Rossi A. Failure of aldosterone suppression despite angiotensin converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001;37:1808.PubMedCrossRefGoogle Scholar
  13. 13.
    Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999;341:753.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303.PubMedCrossRefGoogle Scholar
  15. 15.
    CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429.CrossRefGoogle Scholar
  16. 16.
    SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293.CrossRefGoogle Scholar
  17. 17.
    Cleland JGF, Henderson E, McLenachan J, et al. Effect of captopril, an angiotensin converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol 1991;17:733.PubMedCrossRefGoogle Scholar
  18. 18.
    REN AAL study investigators. Brenner BM, Cooper ME, Zeeuw D de, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861.PubMedCrossRefGoogle Scholar
  19. 19.
    Parving H-H, Lehnert H, Brochner-Mortensen J, et al. for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870.PubMedCrossRefGoogle Scholar
  20. 20.
    Ferner RE, Simpson JM, Rawlings MD. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. BMJ 1987;294:1119.PubMedCrossRefGoogle Scholar
  21. 21.
    Caskey FJ, Thacker EJ, Johnston PA, et al. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 1997;349:620.PubMedCrossRefGoogle Scholar
  22. 22.
    Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983;308: 373.PubMedCrossRefGoogle Scholar
  23. 23.
    Topol EJ, Thomas A, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985;312:277.PubMedCrossRefGoogle Scholar
  24. 24.
    Jett GK. Captopril-induced angioedema. Ann Emerg Med 1984;13:489.PubMedCrossRefGoogle Scholar
  25. 25.
    Giannoccaro PJ, Wallace GJ, Higginson L, et al. Fatal angioedema associated with enalapril. Can J Cardiol 1989;5:335.PubMedGoogle Scholar
  26. 26.
    Cameron DI. Near fatal angioedema associated with captopril. Can J Cardiol 1990;6:265.PubMedGoogle Scholar
  27. 27.
    Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994;308:18.PubMedGoogle Scholar
  28. 28.
    Kochar MS, Bolek G, Kalbfleish JF, et al. A 52 week comparison of lisinopril, hydrochlorothiazide and their combination in hypertension. J Clin Pharmacol 1987;27:373.PubMedGoogle Scholar
  29. 29.
    ATLAS Study Group. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312.PubMedGoogle Scholar
  30. 30.
    Hui KK, Duchin KL, Kripalani KJ, et al. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 1991;49:457.PubMedCrossRefGoogle Scholar
  31. 31.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. for the Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851.PubMedCrossRefGoogle Scholar
  32. 32.
    Khan M Gabriel. Cardiac Drug Therapy, 5th ed. Philadelphia, WB Saunders, 2000, p 53.Google Scholar
  33. 33.
    Bloom BS. Continuation of initial medication after 1 year therapy. Clin Ther 1999;20:671.CrossRefGoogle Scholar
  34. 34.
    ELITE II: Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality on patients with symptomatic heart failure: Randomized trial. The Losartan Heart Failure Study. Lancet 2000;255:1582.CrossRefGoogle Scholar

Suggested Reading

  1. Jhund P, McMurray JV. Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor?: Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. Circulation 2006;113:2566–2568.PubMedCrossRefGoogle Scholar
  2. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–2481.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Personalised recommendations